CK Life Sciences International Holdings (STU:LSI) EBIT: €27.3 Mil (TTM As of Dec. 2025)


STU:LSI CK Life Sciences International Holdings Inc STU:LSI
34 GF Score
Price €0.07
GF Value €0.08
! 5 Warning Signs
View Full Analysis

What is CK Life Sciences International Holdings EBIT?

CK Life Sciences International Holdings STU:LSI -4.35% 34 EBIT is €27.3 Mil as of Dec. 2025. GuruFocus rates STU:LSI with a GF Score™ of 34/100 and a GF Value™ of €0.08. The stock has 5 warning signs investors should review.

CK Life Sciences International Holdings's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was €26.4 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €27.3 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. CK Life Sciences International Holdings's annualized ROC % for the quarter that ended in Dec. 2025 was 0.00%. CK Life Sciences International Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 11.71%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. CK Life Sciences International Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 2.07%.

CK Life Sciences International Holdings  (STU:LSI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

CK Life Sciences International Holdings's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-21.37 * ( 1 - 100% )/( (1058.293 + 1286.493)/ 2 )
=-0/1172.393
=0.00 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1246.776 - 100.349 - ( 88.134 - max(0, 234.071 - 347.752+88.134))
=1058.293

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1299.15 - 63.275 - ( 66.191 - max(0, 380.635 - 330.017+66.191))
=1286.493

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

CK Life Sciences International Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=52.78/( ( (294.542 + max(159.27, 0)) + (298.716 + max(148.542, 0)) )/ 2 )
=52.78/( ( 453.812 + 447.258 )/ 2 )
=52.78/450.535
=11.71 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(117.697 + 140.898 + 1.023) - (100.349 + 0 + -0.0010000000000048)
=159.27

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(106.113 + 135.056 + 19.264) - (63.275 + 0 + 48.616)
=148.542

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

CK Life Sciences International Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=27.323/1322.938
=2.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CK Life Sciences International Holdings EBIT Related Terms

CK Life Sciences International Holdings EBIT Historical Data

* Premium members only.

The historical data trend for CK Life Sciences International Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CK Life Sciences International Holdings EBIT Chart

CK Life Sciences International Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 38.14 44.62 45.91 30.19 27.32

CK Life Sciences International Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.60 20.76 8.75 0.93 26.39

STU:LSI vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, CK Life Sciences International Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CK Life Sciences International Holdings EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CK Life Sciences International Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where CK Life Sciences International Holdings's EV-to-EBIT falls into.


STU:LSI
34GF Score
CK Life Sciences International Holdings Inc STU:LSI
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CK Life Sciences International Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €27.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €27.3 Mil mean?
CK Life Sciences International Holdings (STU:LSI) has a EBIT of €27.3 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on CK Life Sciences International Holdings.
Is CK Life Sciences International Holdings' EBIT too high?
CK Life Sciences International Holdings' current EBIT is €27.3 Mil. Overall, CK Life Sciences International Holdings has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does CK Life Sciences International Holdings' EBIT compare to VRTX and REGN?
CK Life Sciences International Holdings' EBIT of €27.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on CK Life Sciences International Holdings. CK Life Sciences International Holdings's current EBIT is €27.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CK Life Sciences International Holdings stock overvalued right now?
CK Life Sciences International Holdings (STU:LSI) has a current EBIT of €27.3 Mil. The stock's GF Value™ is €0.08, compared to a current price of €0.07 — trading 17.5% below its estimated fair value. The current EBIT is €27.3 Mil. CK Life Sciences International Holdings' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For CK Life Sciences International Holdings (STU:LSI), the current EBIT is €27.3 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CK Life Sciences International Holdings (STU:LSI) Overvalued in 2026?

Based on GuruFocus' analysis, CK Life Sciences International Holdings stock appears to be undervalued. The current stock price of €0.07 is trading 17.5% below its estimated GF Value™ of €0.08.

Key valuation signals for STU:LSI:

  • EBIT: €27.3 Mil
  • GF Value™: €0.08 vs. price of €0.07 (17.5% below fair value)
  • GF Score™: 34/100 with 5 warning signs

No single metric tells the full story. See the STU:LSI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CK Life Sciences International Holdings Business Description

Other Exchanges 00775:Hong Kong
Address 2 Dai Fu Street, Tai Po Industrial Estate, Tai Po, Hong Kong, HKG
CK Life Sciences International Holdings Inc is an international life sciences company. It is engaged in research and development, manufacturing, commercialization, marketing and selling of health and agriculture-related products, as well as investment in a portfolio of vineyards, and various financial and investment products. Its pipeline includes Seviprotimut-L, TTX-MC138, Seviprotimut-L + TTX-MC138, TTX-RIGA, Halneuron, among others. Its segments include Agriculture-related, Nutraceutical, and Pharmaceuticals & Diagnostics R&D with the majority of the revenue deriving from Nutraceutical segment. Geographically it operates in Asia Pacific that derives the majority of the revenue and North America.
34GF Score

Get the complete analysis for STU:LSI

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.07
Price
€0.08
GF Value